Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals Limited reported a strong Q2 2024 performance with DAYBUE™, its Rett syndrome treatment, achieving net sales of US$84.6 million, resulting in A$13 million in royalties for Neuren. The company is optimistic about DAYBUE’s market potential, expecting net sales to reach US$340-370 million in 2024. Additionally, Phase 2 trials of NNZ-2591 showed significant improvements in Pitt Hopkins syndrome, positioning Neuren for further success.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
